1. Home
  2. XGN

as of 12-12-2025 3:36pm EST

$7.13
$0.08
-1.11%
Stocks Health Care Medical Specialities Nasdaq

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Chart Type:
Time Range:
Founded: 2002 Country:
United States
United States
Employees: N/A City: VISTA
Market Cap: 253.9M IPO Year: 2019
Target Price: $13.67 AVG Volume (30 days): 303.7K
Analyst Decision: Strong Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.94 EPS Growth: N/A
52 Week Low/High: $2.67 - $12.23 Next Earning Date: 11-04-2025
Revenue: $63,599,000 Revenue Growth: 14.08%
Revenue Growth (this year): 22.15% Revenue Growth (next year): 15.26%

AI-Powered XGN Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold
Model Accuracy: 74.66%
74.66%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Exagen Inc. (XGN)

ABALLI JOHN

President and CEO

Sell
XGN Oct 16, 2025

Avg Cost/Share

$11.82

Shares

31,787

Total Value

$375,598.37

Owned After

714,427

SEC Form 4

Latest Exagen Inc. News

XGN Breaking Stock News: Dive into XGN Ticker-Specific Updates for Smart Investing

All XGN News

Share on Social Networks: